Landmarks in prostate cancer diagnosis: The biomarkers

BJU International

Volumn 110, Issue SUPPL. 1, 2012, Pages 8-13

  Artibani, Walter ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

biomarkers; diagnosis; prostate cancer; PSA

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ANNEXIN 3; APC PROTEIN; BIOLOGICAL MARKER; CYTOKERATIN; GLUTATHIONE TRANSFERASE P1; INTERLEUKIN 6; KALLIKREIN 3; KI 67 ANTIGEN; MATRIX METALLOPROTEINASE; MESSENGER RNA; ONCOPROTEIN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN P63; RETINOIC ACID RECEPTOR BETA 2; SCATTER FACTOR RECEPTOR; THYMOSIN BETA15; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UROKINASE;

ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; CANCER TEST; CIRCULATING TUMOR CELL; DIAGNOSTIC ACCURACY; DNA METHYLATION; GENE FUSION; GENETIC MARKER; HUMAN; KALLIKREIN 2 GENE; OVERALL SURVIVAL; PCA3 GENE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR BIOPSY; TUMOR GENE;

EARLY DETECTION OF CANCER; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84867549932     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.011429.x     Document Type: Article

References (65)

1. Heidenreich A, Bolla M, Joniau S, et al,. EAU Guidelines on Prostate cancer (2011). Available at: http://www.uroweb.org/gls/pdf/08-Prostate- Cancer%20September%2022nd%202011.pdf. Accessed July 2012
2. Catalona WJ, Richie JP, Ahmann FR, et al,. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151: 1283-90 (Pubitemid 24121936)
3. Thompson IM, Pauler DK, Goodman PJ, et al,. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-46
4. Catalona WJ, Partin AW, Slawin KM, et al,. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: 1542-7 (Pubitemid 28233009)
5. Pepe P, Aragona F,. Incidence of insignificant prostate cancer using free/total PSA: results of a case-finding protocol on 14,453 patients. Prostate Cancer Prostatic Dis 2010; 13: 316-9
6. Roddam AW, Duffy MJ, Hamdy FC, et al,. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005; 48: 386-99
7. Sokoll LJ, Bruzek DJ, Dua R, et al,. Short-term stability of the molecular forms of prostate-specific antigen and effect on percent complexed prostate-specific antigen and percent free prostate-specific antigen. Urology 2002; 60: 24-30
8. Stephan C, Lein M, Jung K, et al,. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer 1997; 79: 104-9 (Pubitemid 26425514)
9. Oberpenning F, Weining C, Brandt B, et al,. Combining free and total prostate specific antigen assays from different manufacturers: the pitfalls. Eur Urol 2002; 42: 577-82 (Pubitemid 35462336)
10. Loeb S, Kettermann A, Ferrucci L, et al,. PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging. Eur Urol 2008; 54: 1073-80
11. Vickers AJ, Savage C, O'Brien MF, Lilja H,. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009; 27: 398-403
12. Catalona WJ, Bartsch G, Rittenhouse HG, et al,. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 2003; 170: 2181-5 (Pubitemid 37413952)
13. Catalona WJ, Bartsch G, Rittenhouse HG, et al,. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol 2004; 171: 2239-44 (Pubitemid 38625443)
14. Le BV, Griffin CR, Loeb S, et al,. [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol 2010; 183: 1355-9
15. Jansen FH, Van Schaik RHN, Kurstjens J, et al,. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010; 57: 921-7
16. Guazzoni G, Nava L, Lazzeri M, et al,. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol 2011; 60: 214-22
17. Aly M, Wiklund F, Grönberg H,. Early detection of prostate cancer with emphasis on genetic markers. Acta Oncol 2011; 50 (Suppl 1): 18-23
18. Kote-Jarai Z, Easton DF, Stanford JL, et al,. Multiple novel prostate cancer predisposition loci confirmed by an international study: The PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev 2008; 17: 2052-61
19. Fitzgerald LM, Kwon EM, Koopmeiners JS, et al,. Analysis of recently identified prostate cancer susceptibility loci in a population-based study: Associations with family history and clinical features. Clin Cancer Res 2009; 15: 3231-7
20. Mitelman F, Johansson B, Mertens F,. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 2007; 7: 233-45 (Pubitemid 46480968)
21. Morris DS, Tomlins SA, Montie JE, Chinnaiyan AM,. The discovery and application of gene fusions in prostate cancer. BJU Int 2008; 102: 276-82 (Pubitemid 352019201)
22. Tomlins SA, Rhodes DR, Perner S, et al,. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-8 (Pubitemid 41528150)
23. Mehra R, Tomlins SA, Shen R, et al,. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007; 20: 538-44 (Pubitemid 46631996)
24. Triptocare study. ClinicalTrials.govWebsite. Available at: http://clinicaltrials.gov/ct2/show/NCT01020448?term=triptocare&rank=1. Accessed January 2012
25. Ali TZ, Epstein JI,. False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells. Am J Surg Pathol 2008; 32: 1890-5
26. Wang W, Sun X, Epstein JI,. Partial atrophy on prostate needle biopsy cores: A morphologic and immunohistochemical study. Am J Surg Pathol 2008; 32: 851-7
27. Zhou M, Shah R, Shen R, Rubin MA,. Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells. Am J Surg Pathol 2003; 27: 365-71 (Pubitemid 36245802)
28. Wu HH, Lapkus O, Corbin M,. Comparison of 34[beta]E12 and P63 in 100 consecutive prostate carcinoma diagnosed by needle biopsies. Appl Immunohistochem Mol Morphol 2004; 12: 285-9 (Pubitemid 39602066)
29. Zhou M, Aydin H, Kanane H, Epstein J,. How often does alpha-methylacyl-CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers? Am J Surg Pathol 2004; 28: 239-43 (Pubitemid 38124733)
30. Magi-Galluzzi C, Luo J, Isaacs WB, et al,. Alpha-methylacyl-CoA racemase: A variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy. Am J Surg Pathol 2003; 27: 1128-33 (Pubitemid 36909534)
31. Murphy AJ, Hughes CA, Lannigan G, et al,. Heterogeneous expression of alpha-methylacyl-CoA racemase in prostatic cancer correlates with Gleason score. Histopathology 2007; 50: 243-51 (Pubitemid 46046393)
32. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP,. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases. Cancer 1998; 82: 2256-61 (Pubitemid 28240834)
33. Ross JS, Sheehan CE, Fisher HA, et al,. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003; 9: 6357-62 (Pubitemid 38031820)
34. Wright GL Jr, Grob BM, Haley C, et al,. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996; 48: 326-34 (Pubitemid 26279634)
35. Sweat SD, Pacelli A, Murphy GP, Bostwick DG,. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998; 52: 637-40 (Pubitemid 28440171)
36. Perner S, Hofer MD, Kim R, et al,. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 2007; 38: 696-701 (Pubitemid 46560805)
37. van Weerdan W, Moerings E, van Kreuningen A, et al,. Ki-67 expression and BrdUrd incorporation as markers of proliferative activity in human prostate tumour models. Cell Prolif 1993; 26: 67-75 (Pubitemid 23088886)
38. Berney DM, Gopalan A, Kudahetti S, et al,. Ki-67 and outcome in clinically localised prostate cancer: Analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer 2009; 100: 888-93
39. Khor LY, Bae K, Paulus R, Al-Saleem T, et al,. MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02. J Clin Oncol 2009; 27: 3177-84
40. de Kok JB, Verhaegh GW, Roelofs RW, et al,. DD3(PCA3), A very sensitive and specific marker to detect prostate tumors. Cancer Res 2002; 62: 2695-8 (Pubitemid 34462754)
41. Hessels D, Klein Gunnewiek JM, van Oort I, et al,. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44: 8-15
42. Andriole G, Bostwick D, Brawley O, et al,. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004; 172: 1314-7 (Pubitemid 39249705)
43. Nakanishi H, Groskopf J, Fritsche HA, et al,. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008; 79: 1804-9
44. Whitman EJ, Groskopf J, Ali A, et al,. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume, J Urol 2008; 180: 1975-8
45. Schostak M, Schwall GP, Poznanovic S, et al,. Annexin A3 in urine: A highly specific noninvasive marker for prostate cancer early detection. J Urol 2009; 181: 343-53
46. Egeblad M, Werb Z,. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-74 (Pubitemid 37328786)
47. Lu Q, Zhang J, Allison R, et al,. Identification of extracellular deltacatenin accumulation for prostate cancer detection. Prostate 2009; 69: 411-8
48. Russo AL, Jedlicka K, Wernick M, et al,. Urine analysis and protein networking identify met as a marker of metastatic prostate cancer. Clin Cancer Res 2009; 15: 4292-8
49. Hutchinson LM, Chang EL, Becker CM, et al,. Development of a sensitive and specifi c enzyme-linked immunosorbent assay for thymosin beta15, a urinary biomarker of human prostate cancer. Clin Biochem 2005; 38: 558-71 (Pubitemid 40693471)
50. Roy R, Louis G, Loughlin KR, et al,. Tumor-specific urinary matrix metalloproteinase fingerprinting: Identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res 2008; 14: 6610-7
51. Harden SV, Sanderson H, Goodman SN, et al,. Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies. J Natl Cancer Inst 2003; 95: 1634-7 (Pubitemid 37455931)
52. Baden J, Green G, Painter J, et al,. Multicenter evaluation of an investigational prostate cancer methylation assay. J Urol 2009; 182: 1186-93
53. Harvey TJ, Hooper JD, Myers SA, et al,. Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4. J Biol Chem 2000; 275: 37397-406 (Pubitemid 32004843)
54. Lintula S, Stenman J, Bjartell A, Nordling S, Stenman UH,. Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue. Prostate 2005; 63: 324-9 (Pubitemid 40664343)
55. Duffy MJ,. Urokinase-type plasminogen activator: A potent marker of metastatic potential in human cancers. Biochem Soc Trans 2002; 30: 207-10
56. Gupta A, Lotan Y, Ashfaq R, et al,. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol 2009; 55: 1124-33
57. Hienert G, Kirchheimer JC, Pfluger H, Binder BR,. Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas. J Urol 1988; 140: 1466-9.
58. Miyake H, Hara I, Yamanaka K, et al,. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 1999; 39: 123-9 (Pubitemid 29194284)
59. Shariat SF, Shalev M, Menesses-Diaz A, et al,. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 2001; 19: 2856-64 (Pubitemid 32538195)
60. Shariat SF, Kattan MW, Traxel E, et al,. Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res 2004; 10: 1992-9 (Pubitemid 38375558)
61. Culig Z, Steiner H, Bartsch G, Hobisch A,. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 2005; 95: 497-505 (Pubitemid 41420180)
62. Michalaki V, Syrigos K, Charles P, Waxman J,. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 2004; 90: 2312-6 (Pubitemid 38961893)
63. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14: 6302-9
64. Pal SK, Twardowski P, Josephson DY,. Beyond castration and chemotherapy: novel approaches to targeting androgen-driven pathways. Maturitas 2009; 64: 61-6
65. Scher HI, Jia X, de Bono JS, et al,. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 2009; 10: 233-9